Q&A: Why Obesity and Diabetes Are Driving the MASLD Epidemic
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1.3 billion people globally, driven by metabolic disease trends, highlighting urgent needs for earlier detection, prevention, and pharmacist-led intervention.
In a written interview with Pharmacy Times, Jiyeon Oh, MD, first author and staff at the Department of Medicine at Kyung Hee University College of Medicine in Seoul, South Korea; Min Seo Kim, MD, MS, corresponding author and staff at the Cardiovascular Disease Initiative, Broad Institute of Massachusetts Institute of Technology and Harvard University; and Dong Keon Yon, MD, PhD, corresponding author and assistant professor in the Department of Pediatrics at Kyung Hee University, discussed the global burden and epidemiologic drivers of metabolic dysfunction-associated steatotic liver disease (MASLD), emphasizing its rapid rise and strong association with metabolic diseases.1